Expansion of Cirmtuzumab/Ibrutinib Study Shows Promise in MCL

Researchers have opened an expansion cohort to include patients with mantle cell lymphoma in the phase I/II CIRLL study to determine if adding cirmtuzumab to ibrutinib can increase the rate of complete remissions.

Source: CancerNetwork - November 12, 2019 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news